Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TDRD6 and SLC25A27 antisense RNA 1 (TDRD6-AS1)
- Target
- TDRD6-AS1
- Molecular classification
- Long noncoding RNA (lncRNA), Antisense RNA, Natural antisense transcript (NAT)
01
Overview
TDRD6 and SLC25A27 antisense RNA 1 (TDRD6-AS1) is a long noncoding RNA transcript that occurs antisense to protein-coding genes TDRD6 and SLC25A27. As a member of the natural antisense transcript (NAT) family, it likely modulates gene expression through complementary interactions with the mRNAs of its sense genes, impacting transcriptional, epigenetic, or RNA processing steps. While general functions of antisense RNAs include roles in cell differentiation, chromatin remodeling, and disease, currently, TDRD6-AS1’s specific biological roles and clinical relevance remain undetermined. It is not considered a classical drug target such as a receptor, enzyme, or transporter, and there are no known drugs, biomarkers of efficacy, or safety issues associated with its modulation.
- Other names
- TDRD6-AS1
02
Mechanism of action
Antisense oligonucleotides (ASOs): Bind target RNAs to modulate splicing, stability, or translation, often inducing RNase H-mediated degradation or blocking translational machinery. No ASO therapy specifically targets TDRD6-AS1 as of now.
03
Biological functions
Regulation of gene expression (via interaction with sense mRNAs or chromatin modulation)Epigenetic regulation (including DNA methylation and histone modification)Regulation of transcription, splicing, and mRNA stabilityPotential involvement in alternative splicing and transcript modulation
04
Disease associations
Cancer (via dysregulated NATs modulating tumor suppressors/oncogenes)Epigenetic disorders (through gene silencing/imprinting errors)Other diseases possibly linked to abnormal antisense RNA expression (e.g., alpha-thalassemia, acute lymphoblastic/myeloid leukemia via similar mechanisms)No specific evidence links TDRD6-AS1 directly to a defined disease at this time
05
Safety considerations
None reported for TDRD6-AS1; general ASO therapies can have off-target or immune effects
Beyond the preview
Go deeper on TDRD6 and SLC25A27 antisense RNA 1 (TDRD6-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TDRD6 and SLC25A27 antisense RNA 1 (TDRD6-AS1).